TRACON Pharmaceuticals, Inc.
(NASDAQ : TCON)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.63%105.161.1%$1250.41m
GILDGilead Sciences, Inc.
0.43%72.820.9%$635.59m
AMGNAmgen Inc.
0.07%169.961.1%$483.52m
BIIBBiogen Inc.
0.24%309.801.2%$426.39m
REGNRegeneron Pharmaceuticals, Inc.
0.81%387.542.7%$354.48m
ALXNAlexion Pharmaceuticals, Inc.
-0.42%107.601.9%$279.93m
VRTXVertex Pharmaceuticals Incorporated
1.33%147.041.9%$234.21m
ALNYAlnylam Pharmaceuticals, Inc
0.24%132.3310.0%$190.13m
INCYIncyte Corporation
0.05%99.002.5%$178.71m
NKTRNektar Therapeutics
-0.46%49.756.1%$170.43m
ILMNIllumina, Inc.
1.56%215.353.5%$165.34m
JUNOJuno Therapeutics, Inc.
2.65%60.3313.5%$136.10m
AAgilent Technologies, Inc.
-1.75%68.691.5%$131.83m
SRPTSarepta Therapeutics, Inc.
0.66%56.2216.8%$117.39m
BLUEBluebird Bio, Inc.
-0.03%167.2017.2%$114.30m

Company Profile

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company products include TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, TRC205 an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals was founded in October 2004 and is headquartered in San Diego, CA.